Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

被引：25

作者：

Stilgenbauer, Stephan ^{[1
]}

Eichhorst, Barbara F. ^{[2
]}

Schetelig, Johannes ^{[3
]}

Coutre, Steven ^{[4
]}

Seymour, John F. ^{[5
]}

Munir, Talha ^{[6
]}

Puvvada, Soham D. ^{[7
]}

Wendtner, Clemens-Martin ^{[8
]}

Roberts, Andrew W. ^{[9
]}

Jurczak, Wojciech ^{[10
]}

Mulligan, Stephen ^{[11
]}

Boettcher, Sebastian ^{[12
]}

Mobasher, Mehrdad ^{[13
]}

Zhu, Ming ^{[14
]}

Chyla, Brenda ^{[14
]}

Verdugo, Maria ^{[14
]}

Enschede, Sari Heitner ^{[14
]}

Cerri, Elisa ^{[14
]}

Humerickhouse, Rod A. ^{[14
]}

Gordon, Gary ^{[14
]}

Hallek, Michael ^{[2
]}

Wierda, William ^{[15
]}

机构：

[1] Univ Ulm, D-89069 Ulm, Germany

[2] Univ Cologne, Dept Internal Med, D-50931 Cologne, Germany

[3] Univ Hosp TU Dresden, Dept Med 1, Dresden, Germany

[4] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] St Jamess Inst Oncol, Leeds, W Yorkshire, England

[7] Univ Arizona, Ctr Canc, Tucson, AZ USA

[8] Hosp Munich Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[9] Royal Melbourne Hosp, Melbourne, Vic, Australia

[10] Jagiellonian Univ, Krakow, Poland

[11] Royal N Shore Hosp, Dept Haematol, St Leonards, NSW 2065, Australia

[12] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[13] Genentech Inc, San Francisco, CA 94080 USA

[14] AbbVie Inc, N Chicago, IL USA

[15] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.LBA-6.LBA-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 19 条

[1] INTERIM QUALITY OF LIFE RESULTS WITH VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DEL(17P) CHRONIC LYMPHOCYTIC LEUKEMIA
Wierda, W.
Cifaldi, M.
Hsu, Li
Cerri, E.
Verdugo, M. E.
HAEMATOLOGICA, 2016, 101 : 148 - 148
[2] VENETOCLAX (ABT-199/GDC-0199) COMBINED WITH RITUXIMAB INDUCES DEEP RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Roberts, A. W.
Ma, S.
Brander, D.
Kipps, T. J.
Barrientos, J. C.
Davids, M. S.
Anderson, M. A.
Choi, M.
Tam, C.
Magee, L.
Kreutzer, J.
Singh, R.
Kim, J.
Dimovski, B.
Mason-Bright, T.
Prine, B.
Zhu, M.
Humerickhouse, R. A.
Seymour, J. F.
HAEMATOLOGICA, 2015, 100 : 154 - 154
[3] Venetoclax (ABT-199/GDC-0199) combined with rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia
Ma, Shuo
Roberts, Andrew W.
Brander, Danielle
Kipps, Thomas J.
Barrientos, Jacqueline C.
Davids, Matthew S.
Anderson, Mary Ann
Choi, Michael
Tam, Constantine
Magee, Lisa
Kreutzer, Jennifer
Kim, Jennifer
Dimovski, Belinda
Mason-Bright, Tanita
Prine, Betty
Zhu, Ming
Humerickhouse, Rod A.
Seymour, John F.
LEUKEMIA & LYMPHOMA, 2015, 56 : 21 - 21
[4] IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PHASE 2, OPEN-LABEL STUDY OF VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY
Wierda, W.
Sail, K.
Noe, L.
Kamalakar, R.
Gdovin, J.
Verdugo, M.
Kim, S.
Humerickhouse, R.
Stilgenbauer, S.
HAEMATOLOGICA, 2017, 102 : 599 - 599
[5] Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy
Jones, Jeffrey
Mato, Anthony R.
Coutre, Steven
Wierda, William
Choi, Michael Y.
Davids, Matthew S.
Lamanna, Nicole
Barr, Paul
Burns, Kim
Montalvo, Nicholas
Zhu, Ming
Busman, Todd
Potluri, Jalaja
Humerickhouse, Rod A.
Byrd, John C.
BLOOD, 2015, 126 (23)
[6] A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphosytic leukemia (CLL) harboring 17p deletion
Wierda, William G.
Seymour, John Francis
Roberts, Andrew Warwick
Puvvada, Soham
Davids, Matthew Steven
Wong, Shekman
Zhu, Ming
Carrl, Elisa
Humerickhouse, Rod
Stilgenbauer, Stephan
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study
Ma, Shuo
Brander, Danielle M.
Seymour, John F.
Kipps, Thomas J.
Barrientos, Jacqueline C.
Davids, Matthew S.
Anderson, Mary Ann
Choi, Michael Y.
Tam, Constantine S.
Mason-Bright, Tanita
Prine, Betty
Munasinghe, Wijith
Zhu, Ming
Kim, Su Young
Humerickhouse, Rod A.
Roberts, Andrew W.
BLOOD, 2015, 126 (23)
[8] THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IS ACTIVE AND WELL-TOLERATED IN ULTRA HIGH-RISK RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Roberts, A.
Davids, M.
Pagel, J.
Kahl, B.
Wierda, W.
Miller, T.
Gerecitano, J.
Kipps, T.
Anderson, M.
Huang, D.
Darden, D.
Gressick, L.
Nolan, C.
Yang, J.
Busman, T.
Graham, A.
Cerri, E.
Enschede, S.
Humerickhouse, R.
Seymour, J.
HAEMATOLOGICA, 2013, 98 : 473 - 473
[9] Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Seymour, John F.
Davids, Matthew S.
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Miller, Thomas P.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary-Ann
Huang, David C. S.
Rudersdorf, Nikita K.
Gressick, Lori A.
Montalvo, Nicholas P.
Yang, Panning
Busman, Todd A.
Dunbar, Martin
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew W.
BLOOD, 2013, 122 (21)
[10] ABT-199 (GDC-0199) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: HIGH RESPONSE RATES AMONG PATIENTS WITH HIGH RISK DISEASE FEATURES INCLUDING UNMUTATED IGHV
Seymour, J. F.
Davids, M. S.
Pagel, J. M.
Kahl, B. S.
Wierda, W. G.
Puvvada, S.
Gerecitano, J. F.
Kipps, T. J.
Anderson, M. A.
Huang, D. C.
Rudersdorf, N. K.
Gressick, L. A.
Montalvo, N. P.
Yang, J.
Zhu, M.
Dunbar, M.
Cerri, E.
Enschede, S. H.
Humerickhouse, R. A.
Roberts, A. W.
HAEMATOLOGICA, 2014, 99 : 249 - 249

← 1 2 →